For questions about BMS medicines during this time,
please call 1-800-721-8909.

Proven to relieve
symptoms like joint
pain and swelling

moderate to severe rheumatoid arthritis patient

ORENCIA has been shown to help many different types of people with moderate to severe RA. Which one are you?

Select a tab based on your experience

This clinical study showed that ORENCIA intravenous (IV) infusion and methotrexate improved results compared with methotrexate alone. 256 people were in the ORENCIA group, and 253 people were in the methotrexate group. Most people in this study were dual seropositive, which means they tested positive for anti-CCP and rheumatoid factor (RF).

Anti-CCP, anti-cyclic citrullinated peptide.

After 1 year of treatment:

Lowered disease activity

41% of people achieved a low level of disease activity with ORENCIA and methotrexate compared with 23% of people taking methotrexate alone based on disease scores.

Reduced further joint damage

ORENCIA and methotrexate reduced further joint damage more than methotrexate alone based on changes in X-ray scores (0.6 vs 1.1).

Reduced symptoms by 50%

57% of people felt symptom relief with ORENCIA and methotrexate compared with 42% of people taking methotrexate alone based on symptom scores.

At your next visit, ask your doctor if you're dual seropositive

What was the purpose of this study?

This study looked at the efficacy and safety of ORENCIA IV and methotrexate compared with methotrexate alone after 1 year.

Some characteristics that people needed to have in order to be included in this study:

  • At least 18 years old
  • Diagnosed with RA for 2 years or less
  • Living with active RA
  • Never treated with methotrexate or given methotrexate for a limited period of time
  • Positive for anti-CCP and/or rheumatoid factor (RF)
  • Known to have joint damage in their hands, wrists, or feet
  • Known to have poor risk factors
  • 10 or more swollen joints, 12 or more tender joints

What else should I know about the people in this study?

89% of people tested positive for anti-CCP and 96.5% tested positive for RF. 86% of people tested positive for both, meaning that most people were considered dual seropositive. People had been living with RA for an average of 6.5 months.

What was compared in this study?

The 509 people in this study were randomly placed into 2 groups to help compare their responses to treatment. One group of 256 people received ORENCIA with methotrexate, and the other group of 253 people received methotrexate alone.

Anti-CCP, anti-cyclic citrullinated peptide.

This clinical study showed that ORENCIA IV infusion and methotrexate improved results compared with methotrexate alone in people
who weren’t helped by methotrexate previously. 424 were in the ORENCIA and methotrexate group, and 214 people were in the
methotrexate group.

After 6 months of treatment:

After 1 year of treatment:

Reduced symptoms

68% of people felt symptom relief with ORENCIA and methotrexate compared with 40% of people taking methotrexate alone based on symptom scores.


Improved physical function

64% of people saw an improvement in physical function with ORENCIA and methotrexate compared with 39% of people taking methotrexate alone based on activity scores.

Reduced further joint damage

ORENCIA and methotrexate reduced further joint damage by 50% compared with methotrexate alone based on X-ray scores (0.25 vs 0.53).

What was the purpose of this study?

This study looked at the efficacy and safety of ORENCIA IV and methotrexate compared with methotrexate alone after 6 months and then after 1 year in people who weren't helped enough by methotrexate.

Some characteristics that people needed to have in order to be included in this study:

  • At least 18 years old
  • Diagnosed with RA for at least 1 year
  • Living with active and persistent RA, despite treatment with methotrexate
  • Treated with methotrexate for at least 3 months
  • 10 or more swollen joints, 12 or more tender joints

What else should I know about the people in this study?

On average, people who were in the ORENCIA and methotrexate group were 51.5 years old and had been living with RA for 8.5 years.

What was compared in this study?

The 638 people in this study were randomly placed into 2 groups to help compare their responses to treatment. One group of 424 people received ORENCIA with methotrexate, and the other group of 214 people received methotrexate alone.

This clinical study showed that ORENCIA IV infusion and DMARDs improved results compared with DMARDs alone. 256 people were in the ORENCIA group, and 133 people were in the DMARD group. People in this study weren’t helped enough by TNF blockers. Examples of TNF blockers include Humira® (adalimumab), Enbrel® (etanercept), or Remicade® (infliximab).

DMARD, disease-modifying antirheumatic drugs; TNF, tumor necrosis factor.

After 6 months of treatment:

Reduced symptoms

50% of people felt symptom relief with ORENCIA and DMARDs compared with 20% of people taking DMARDs alone based on symptom scores.

Improved physical function

47% of people saw an improvement in physical function with ORENCIA and DMARDs compared with 23% of people taking DMARDs alone based on activity scores.

What was the purpose of this study?

This study looked at the efficacy and safety of ORENCIA IV and DMARDs compared with DMARDs alone after 6 months.

Some characteristics that people needed to have in order to be included in this study:

  • At least 18 years old
  • Diagnosed with RA for at least 1 year
  • Living with active RA
  • Weren’t helped enough by TNF blockers after at least 3 months of treatment
  • 10 or more swollen joints, 12 or more tender joints

What else should I know about the people in this study?

On average, people who were in the ORENCIA group were 53 years old and had been living with RA for 12 years.

What was compared in this study?

The 389 people in this study were randomly placed into 2 groups to compare their responses to treatment. One group of 256 people received ORENCIA with DMARDs, and the other group of 133 people received DMARDs alone.

How long does it take for ORENCIA to work?

It’s important to know that it may take a
little while for you to respond to your new treatment. Many people started feeling better in about
3 to 6 months. Individual results may vary.

Track your results on ORENCIA with a treatment journal